Skip to main content

Advertisement

SpringerLink
Log in

When good drugs go bad

  • Commentary
  • Published:

From Nature

View current issue Submit your manuscript

How can we best reduce the risk of severe adverse reactions to marketed drugs? An international group of scientists argues that a global research network is needed to identify genetically at-risk populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Institute of Medicine report The Future of Drug Safetyhttp://www.iom.edu/CMS/3793/26341/37329.aspx

  2. Lazarou, J., Pomeranz, B. H. & Corey, P. N. J. Am. Med. Assoc. 279, 1200–1205 (1998).

    Article  CAS  Google Scholar 

  3. van der Hooft, C. S. et al. Drug Saf. 29, 161–168 (2006).

    Article  Google Scholar 

  4. Huang, S. M. et al. Toxicol. Mech. Meth. 16, 89–99 (2006).

    Article  CAS  Google Scholar 

  5. Beutler, E. Pharmacol. Rev. 21, 73–103 (1969).

    CAS  PubMed  Google Scholar 

  6. Roden, D. M. et al. Ann. Intern. Med. 145, 749–757 (2006).

    Article  Google Scholar 

  7. Hazell, L. & Shakir, S. A. Drug Saf. 29, 385–396 (2006).

    Article  Google Scholar 

  8. Molokhia, M. & McKeigue, P. Pharmacogenomics 7, 633–638 (2006).

    Article  CAS  Google Scholar 

  9. Johnson, T. N. Toxicology 192, 37–48 (2003).

    Article  CAS  Google Scholar 

  10. Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. Annu. Rev. Med. 57, 119–137 (2006).

    Article  CAS  Google Scholar 

  11. Roden, D. M. N. Engl. J. Med. 350, 1013–1022 (2004).

    Article  CAS  Google Scholar 

  12. Watkins, P. B. & Seeff, L. B. Hepatology 43, 618–631 (2006).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kathleen M. Giacomini is in the Department of Biopharmaceutical Sciences, University of California, San Francisco,

    Kathleen M. Giacomini

  2. Ronald M. Krauss is at the Childrens Hospital Oakland Research Institute,

    Ronald M. Krauss

  3. Dan M. Roden is at the Vanderbilt University School of Medicine,

    Dan M. Roden

  4. Michel Eichelbaum is at the Stuttgart Institut Klinische Pharmakologie,

    Michel Eichelbaum

  5. Michael R. Hayden is at the University of British Columbia,

    Michael R. Hayden

  6. Yusuke Nakamura is at the University of Tokyo.,

    Yusuke Nakamura

Authors
  1. Kathleen M. Giacomini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald M. Krauss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan M. Roden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michel Eichelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael R. Hayden
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yusuke Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giacomini, K., Krauss, R., Roden, D. et al. When good drugs go bad. Nature 446, 975–977 (2007). https://doi.org/10.1038/446975a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/446975a

  • Springer Nature Limited

This article is cited by

Search

Navigation